In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00174-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Liang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Meropenem, Microbial Sensitivity Tests, Boronic Acids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Mycobacterium abscessus (MAB) infections pose a growing public health threat. Here, we assessed the in vitro activity of the boronic acid-based β-lactamase inhibitor, vaborbactam, with different β-lactams against 100 clinical MAB isolates. Enhanced activity was observed with meropenem and ceftaroline with vaborbactam (1- and >4-fold MIC 50 / 90 reduction). CRISPRi-mediated bla MAB gene knockdown showed a fourfold MIC reduction to ceftaroline but not the other β-lactams. Our findings demonstrate vaborbactam’s potential in combination therapy against MAB infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
- Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
- Department of Medicine, National Jewish Health, Denver, Colorado, USA.
- The University of Colorado, Aurora, Colorado, USA.
ORCID-Profile: Liang Chen, Vinicius Calado Nogueira de Moura, Barry N Kreiswirth
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Chen, L., Shashkina, E., Kurepina, N., Calado Nogueira de Moura, V., Daley, C. L., & Kreiswirth, B. N. (2024). In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00174-24
Vancouver
Chen L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, Daley CL, Kreiswirth BN. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00174-24
BibTeX
@article{Chen2024,
author = {Chen, Liang and Shashkina, Elena and Kurepina, Natalia and Calado Nogueira de Moura, Vinicius and Daley, Charles L and Kreiswirth, Barry N},
title = {In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00174-24}
}
EUVIMED